Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...
An in-depth look at Adaptimmune's TCR T cell therapy program
Rumination, notes and updates on CAR-T cell therapy, checkpoint blockade, SCLC, genomics and TCR signalling...
One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
Where are Blueprint going with their various programs involving targeted therapies in a range of different cancers?
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
Update on TLR9 as a target and what we learn from the latest clinical data
Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...
Highlights and Lowlights amongst targeted therapy data at ASCO 2018
Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.
Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).
The promise and pitfalls of Day 1 of #ASCO18
We explore the importance of looking under the hood at various expression levels...
Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?
It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…
Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?
A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18
What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen
Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?
What to watch out for at ASCO18 in the oral presentation sessions
A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers
A look at path to market strategies open to a small biotech in the CAR-T cell space
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18
A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?
Answering questions on the 1L NSCLC data presented at #AACR18
A look at the latest 1L NSCLC trial readouts
A look at the Class of 2018 new products in development - a hit or miss?
A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.
How can we improve on monotherapy with PARP inhibitors?
How do we address primary and acquired resistance?
Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?
Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?
A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination
What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?
A look at the clinical features that predict for early discontinuation with checkpoint blockade in ovarian cancer
An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.
What can we learn from the early data exploring PARPi plus checkpoint blockade combinations in ovarian cancer?
A post mortem of the Rova-T TRINITY trial and a look to the future in SCLC
A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at the history of NK cell development and where we're going in future with this IO approach
Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area
Some key highlights from the recent inaugural pancreatic cancer symposium in Houston
A look at an emerging area for biomarkers and stealth cancer therapeutics
A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space
What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?
A look at innate approaches to stimulating the immune system including IL-15 agonists
Insights from researchers in the CD47 niche - what do they really think?
A look at the players in controversial CD47-SIRPα landscape
A look at the changing face of the RCC landscape, including current and near term trial readouts
As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?
A look at some new targeted and IO combinations in development for advanced prostate cancer
Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?
A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space
Highlights and Lowlights from ASCO GU 2018 - what to watch out for.
Interview with Dr Daniel George on Phase 3 PROSPER trial results
BMS announced that CM-227 hit PFS in lung cancer patients with high tumour mutation load, now what?
A look at Dr Malcolm Brenner's work on virus specific T cell therapies
FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?
At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.
Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.
A look at where we are in pancreatic cancer and how the landscape has evolved of late...
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.
PharmaMar's lurbinectedin misses in phase 3 platinum resistant ovarian cancer
A look at 8 key abstracts being presented at #GI18 in San Francisco this week.
How does positive trials from Roche and Merck impact the 1L NSCLC landscape?
A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours
Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco
Interview with Syros Pharma CEO Dr Nancy Simonian
Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco
Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco
New series on Key Trends in Oncology for 2018
New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
Where is the venetoclax BCL-2 program going in hematologic malignancies?
An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17
As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?
Commentary on Sunday at 2017 ASH annual meeting in Atlanta
A look at some of the sessions and learnings from the first day at ASH 2017
People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...
The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?
A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).
A look at what's hot in CAR T cell therapies at #ASH17
The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!
A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?
A look at loss of heterozygosity and what it means for new lung cancer therapies
Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...
A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend
A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer
A look at Nektar's promising IO portfolio and what's next for the up and coming biotech
Ten stars from the clinical presentations on Day 2 of SITC 2017
A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset
A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.
Final SITC17 Preview and a look at key talks now that the abstracts are available.
A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly
Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.
A look at up and coming emerging therapies in the DLBCL space
Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia
Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia
A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout
A look at the SCLC landscape including some promising new developments
A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC
What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
A look at some of the LBA posters to be presented at #SITC17 in November
A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for
Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?
Our latest predictions in 1L NSCLC and what to expect from the upcoming trial readouts in this niche
A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?
A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.
Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals
A look at Ugur Sahin's BioNTech and personalized mRNA vaccines
Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?
Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...
After pseudoprogression, the IO field has moved onto hyperprogression. What is it and why does it matter?
Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?
A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC
An early look at a new IO combination that may help overcome resistance to checkpoint therapy
A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore
A roundup of the key trials and targets presented on Sunday at #ESMO17
A look at mostly lung cancer highlights from the first 2 days at #ESMO17
Rucaparib likely joins the early maintenance PARP club in ovarian cancer with their ARIEL3 data at #ESMO17
A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17
8 key ImmunoOnc studies being presented at #ESMO17 this month
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?
A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...
After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...
An eclectic selection of important abstracts involving targeted therapies to watch out for at #ESMO17
A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma
Top 5 IO oral abstracts to watch out for in Madrid
A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist
A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.
A look at AZN's miss with their IO-IO combination in 1L NSCLC
A look at why checkpoint therapy trials might be giving us inconsistent results of late
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
How we could use our immune system against Alzheimer's?
A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?
A second look at the evolving 1L NSCLC landscape with a focus on MYSTIC and IMpower150
Commentary on 2017 Paris Immuno-Oncology summit organised by European Academy of Tumor Immunology and Miltenyi Biotec
July Journal Club explores some intriguing new data around a cancer immunotherapy theme
A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.
Notes on HGSOC, melanoma resistance and the evolution of NSCLC...
Coverage of European Association for Cancer Research EACR cancer genomics conference at Churchill College, Cambridge
Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.
Commentary from Day 1-2 of the 3rd EACR meeting on Cancer Genomics
A look at how liver mets can negatively impact cancer immunotherapies
What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?
What's new in the sarcoma space? Which novel approaches are worth watching out for?
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
Thought leader reactions and sentiments to the APHINITY readout in adjuvant HER2+ breast cancer
A look at checkpoint blockade in early stage breast cancer - encouraging or not?
A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO
Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?
A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).
Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?
Right now many people are overwhelmed not just with the sheer number of ASCO abstracts to process and…
Our Top 10 #ASCO17 abstracts to watch out for
Some intriguing surprises in the CAR T cell therapy abstracts this year...
A look at the FDA briefing docs on Puma's neratinib
A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade
A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!
Update on #ASCO17 data for IDO1 inhibitors in various cancers
A fireside chat with a leading KOL involved in cancer research on resistance.
Durvalumab grabs pole position in unresectable NSCLC amongst IO compounds
We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?
A look a one company's approach to DDR and potential combination opportunities in this niche
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
BSB Reader Mailbag on TRK/ROS1/ALK inhibitors
An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition
Through the keyhole with a look at AZN and MedImmune's IO portfolio
Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts
Encouraging new developments in GBM with a novel CAR T cell therapy
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.
Five emerging cancer research trends we picked up at AACR17 that you should be aware of.
Interview with Professor Peter Schmid, Barts Cancer Institute.
Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.
Commentary on Monday at the 2017 AACR annual meeting.
Commentary on Sunday at the 2017 AACR annual meeting
Highlights from Day 1 at AACR17
A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting
The third PARP inhibitor in ovarian cancer hits the market - what's the latest story?
A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends
A look at how research into transcription factors, super enhancers, chromatin regulation and broom/chromodomains is changing the way we look at cancer
With increasing competition in the CDK4/6 space in HR+ HER2- metastatic breast cancer, how are things shaping up?
Latest BSB reader Q&A looks at 5 questions from subscribers
A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years
PARP! PARP! What's hot in ovarian cancer at SGO and AACR?
Overcoming immune suppression in the tumour microenvironment
After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in…
A look at some recent clinical data and what we can learn from the new data expected at AACR in DC
The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here
6 key trends and highlights of note from the inaugural ASCO-SITC meeting in Orlando, Florida
After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?
A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.
After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.
A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.
Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...
A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.
Reader Q&A on women's cancers relating to HER2, PARP and TNBC...
A look at what we can learn from some recently published new papers in the oncology space.
Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?
What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
A draft manifesto for IO in cancer research and what we need to learn
2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...
A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?
A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.
Will gastric cancer be one of the next indications for nivolumab?
How crowdsourcing data from breast cancer patients may help future clinical R&D
Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?
A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape
SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.
SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.
Update on Neon Tx as they move into commercial new product development with their neoantigen platform.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.
Commentary on Wednesday at JPM17 in San Francisco
Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco
Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
A look at some promising agents in new product development emerging in early CLL trials
How are recently approved novel therapies impacting the CLL landscape and where are we going next?
A look at the latest data for a CD79b targeted ADC in lymphomas
A look at the emerging trends we can expect in 2017 for cancer research
An in-depth look at the sudden and unexpected announcement underlying the clinical hold for Seattle Genetics anti-CD33 ADC Vadastuximab Talirine in AML.
Tackling heterogeneity in older people with AML using novel targeted therapies.
#LeonardList showcases 10 Lymphoma Abstracts at ASH16
We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH
3 trends from SABCS16 that you may hear more about
A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma
We answer several critical questions that readers have sent in based on the CAR T cell data at ASH this week.
Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions
Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich
Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?
Highlights from the Charles River Immunotherapy Symposium in Munich, 2016
If you have plans to be in San Diego for #ASH16 what should you attend on Friday?
A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...
A look at new ways to boost checkpoint therapy performance including agents in development from small biotechs
Update on important new data in urothelial cancers and how the landscape is moving quickly
Does adding lirilumab to nivolumab move the needle in relapsed SCCHN?
An in-depth review of what to expect from AML new product development in San Diego
What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016
Initial impressions of abstracts for ASH16 in San Diego
Four more combination trials of interest in cancer research that may be worth watching out for
Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Can biomarkers help us improve clinical trial outcomes?
How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?
Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented
Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…
Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium
Commentary on Day 2 at ESMO16
What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.
Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.
Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay
Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16
Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.
Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.
New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.
Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).
Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company
Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.
Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.
A look at some of the key breast cancer abstracts to watch out for at #ESMO16 in Copenhagen
Five key approaches in developmental therapeutics in the spotlight at ESMO16
A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect
What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?
A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?
Overcoming barriers to resistance in epithelial cancers - a look at a novel oncogenic target
Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion
Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer
Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.
An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours
A primer on the oncolytics viral therapy landscape - beyond T-VEC
This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.
Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...
A primer on neoantigens and their importance in cancer research
The BMS CheckMate-026 trial in 1L NSCLC did not meet it's primary endpoint. What can we learn from the failure?
Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?
What factors contribute to resistance with checkpoint blockade and how can this be overcome?
July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...
Lilly and Boehringer Ingelheim have announced a clinical trial collaboration in metastatic breast cancer with the CDK4/6 inhibitor, abemaciclib, and the IGF antibody, BI 836845.
A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before
Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?
Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
How will niraparib impact the ovarian cancer market?
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.
Can we turn a cold tumour into a hot one where some patients can respond to therapy?
Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers
An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Can we find and use several biomarkers to triangulate responders and non-responders?
A look at the increasingly competitive metastatic urothelial carcinoma landscape
What to make of the various combination trials presented at ASCO 2016?
A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?
Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago
Prior to chemotherapy men with advanced prostate cancer did not live longer if they received ipilimumab compared to just receiving placebo. The phase 3 trial was a failure.
Top-line commentary from Sunday at ASCO 2016 annual meeting.
Top-line commentary from Saturday at ASCO 2016 annual meeting.
What are our Top Ten immunotherapy abstracts of note at ASCO 2016?
The poster childs for targeted therapies have been surprising - CML and lung cancer -- what's new here at #ASCO16?
The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
A look at Bayer's early oncology pipeline and a curious new class called MNK (Mink) inhibitors
What can we learn about clinical trial design from immunotherapy combinations?
Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
A look at small biotechs producing quality preclinical data at #AACR16 that may lead to clinical development in the near future
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition?
Early proof of concept in patients with metastatic colorectal cancer.
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...
Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag
Can we use technological approaches from oncology to applying creative ways to treating bacterial infections?
Commentary on Tuesday sessions at AACR 2016 annual meeting
Commentary on Monday at AACR 2016 annual meeting
Commentary from Sunday at 2016 AACR annual meeting
Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.
Where next for Bcl2 inhibitors beyond CLL and Del17p? Which novel combinations might be an attractive strategy?
First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.
In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).
Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.
There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.
This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.
The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.
A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
Commentary on some of the latest cancer immunotherapy papers
Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news
Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions
Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.
Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...
Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO
Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii
How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?
What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?
Will checkpoint blockade be effective in multiple GI cancers and if so, why?
A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.
A novel non-invasive liquid biopsy may offer a potential novel biomarker that will help in sequencing prostate cancer drugs.
How do we overcome resistance to Zytiga? There are some encouraging developments in this area to report.
Two biotech companies are in a race to market for a novel target in advanced prostate cancer.
Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco
Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.
Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.
An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.
An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.
ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.
A look at the new CLL 17p deletion data at ASH in the late breaker session
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
Five promising new agents in development for the treatment of ER+ or HER2+ or triple negative breast cancer emerge from #SABCS15
Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers
Commentary on "Manic Monday" at ASH 2015
Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.
Commentary on Saturday at ASH15
In the last of our American Society of Hematology (ASH) 2015 annual meeting previews, we take a broad…
There are an encouraging number of promising therapies in development for Aggressive Lymphomas at ASH this year - which ones should you watch out for?
With four new approvals in multiple myeloma in 2015, ASH is expected to have a surfeit of riches to review for this disease...
Where is the field of immune biomarkers going beyond PD-L1 in the next few years?
Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?
At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.
A look at the FLT3 AML landscape - what's new?
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
Preview of some of the late-breaking abstracts at the 2015 annual meeting of the American Society of Hematology ASH15 in Orlando.
Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations
Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.
AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.
Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?
Review of the highlights from the SITC 2015 pre-meeting workshops
Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online.
This is a quick initial preview of a few that caught my attention in the immunotherapy space.
Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015
Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.
Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...
Finding a biomarker for EGFR monoclonal antibodies in colon cancer has proven elusive but things may be a-changin'...
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
Some promising new clinical targets emerged at ECC in Vienna, including DLL3 in SCLC, TRK gene rearrangements, Notch3 and PTK7. What did we think of the data and what issues should you look out for?
Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?
At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.
Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test?
The debate is heating up!
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Commentary on Day 3 of the European Cancer Congress in Vienna
Commentary on Day 2 of the European Cancer Congress in Vienna
Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna
What happens when we literally step on the gas with immune agonists?
T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?
Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...
What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
The role of basket trials in small cancer subsets will be important to defining what targeted therapies work well...
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?
Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...
Some interesting potential new therapeutic approaches on the horizon in pediatric ALL - beyond CAR T cell therapies lie Bcl2 inhibitors
Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?
Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...
This month's Biotech Strategy Blog mail bag.
Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline
As we learn more about mechanisms of resistance in ALK+ and T790M mutated lung cancer, combination strategies are likely to evolve - but which ones?
Clovis have started their rolling NDA for rociletinib in T790M-positive lung cancer - what about AstraZeneca's AZD9291?
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
What's hot in soft tissue sarcomas at ASCO 2015? Find out more...
Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...
We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...
Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody
How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?
Highlights from Monday at the 2015 ASCO annual meeting in Chicago
What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.
Highlights from Day 2 at ASCO 15 in Chicago
Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.
Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma
At AUA 2015 in New Orleans, Dr Celestia Higano (Seattle) presented the results of the STRIVE clinical trial.
Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.
First in a series of previews of ASCO 2015 annual meeting abstracts.
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."
What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...
What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?
Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?
New developments in T790M and ALK lung cancer plus a look at antibodies targeting ADAM17 in head & neck cancer.
Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?
As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?
The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.
Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.
Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.
Updated data for the AURA phase 1 trial of AZD9291 was presented at the European Lung Cancer Conference in Geneva.
Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...
Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.
The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.
Update in the PREVAIL trial in chemotherapy naive castrate resistant prostate cancer based on 765 deaths from the 2015 EAU conference in Madrid.
The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.
Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.
What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.
Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?
Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...
What's hot at ASCU GU 2015? Focus on prostate and bladder cancers with checkpoint inhibitors and sequencing therapies
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
The ongoing story of the AR-V7 splice variant as a potential biomarker of response in mCRPC
Which new combinations could improve outcomes for colon cancer patients receiving EGFR therapies by overcoming acquired resistance?
We've seen very little real progress in colorectal cancer beyond incremental improvements since Erbitux and Avastin were approved a decade ago. Are we on the threshold of a new paradigm shift?
Patients with BRAF driven colon cancer don't do as well as those with melanoma: how can we overcome acquired resistance to RAF treatment?
Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.
What does the evolving landscape for CAR, TIL and TCR cell therapies look like?
The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.
ABT-199 is now known as venetoclax - has it overcome it's checkered history to get back on track?
Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.
The Phase 2 TERRAIN trial met its primary endpoint (PFS) with enzalutamide beating out bicalutamide in castrate resistant prostate cancer. What next?
Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.
If we truly want to see a more precision medicine approach evolve then we have to first find the oncogenic drivers. At ASCO GI one study in particular caught my eye and attention, but you won’t find it written up in the medical lay press and it’s not that obvious unless you know what you’re looking for.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.
In the last post of 2014, it’s time to address some pertinent questions on triple negative breast cancer (TNBC).
There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?
"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!
Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.
It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.
There are a lot of new products in development for AML. Here's my top 10 abstracts to watch out for at ASH 2014 in San Francisco.
Preview of ASH 2014 Key Abstracts in Lymphomas including HL and aggressive DLBCL
ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace
The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.
Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed
Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona
Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona
How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.
At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.
At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.
OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.
Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).
Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy
This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD.
We’re excited to be attending this meeting for the first time.
There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.
Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?
Checkpoint inhibitors are looking very promising in advanced gastric cancer
Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?
Posters on new cancer drugs in development with novel targets were presented at ESMO 2014 Congress in Madrid.
Advances in Metastatic Colorectal Cancer may come from new druggable targets according to ESMO 2014 CRC Symposium
How is the ALK+ lung cancer market developing now that there are multiple next generation competitors following on from Xalkori and Zykadia? Check out our analysis of the developing landscape...
At ESMO 2014 Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute) presented the results of the Tokai Pharmaceuticals ARMOR2 clinical trial of galeterone in men with advanced prostate cancer.
Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.
Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid
ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.
Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.
There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.
A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014
Update on what to watch out for in immunotherapy at ESMO 2014.
Preview of some important breast cancer trials being presented in Madrid at #ESMO14.
With the recent FDA approval of Pembrolizumab (Keytruda) we can expect melanoma to be a hot topic at ESMO 2014.
Preview of Prostate Cancer oral presentations at ESMO 2014 Cancer Congress in Madrid.
Review of the preliminary programme and late breakers in the Presidential Symposia at ESMO 2014.
To get more cancer therapies to the right patients faster, we need to find better surrogate markers or biomarkers of response that are inextricably linked to survival.
Amgen's phase III FOCUS trial of carfilzomib (Kyprolis) in relapsed/refractory multiple myeloma failed to meet its primary endpoint of overall survival.
Tokai Pharmaceuticals ($TKAI) have filed plans for a $75M IPO, largely based on the potential of their phase 2 prostate cancer compound, galeterone. What is the prostate cancer market opportunity for $TKAI?
Amgen announced the results of the phase III ASPIRE clinical trial for Kyprolis. What impact will this data have on the multiple myeloma landscape?
New CLL therapies that stand out in a rapidly changing CLL landscape include obinutuzumab (Gazyva), ibrutinib (Imbruvica) idelalisib (Zydelig), ABT-199/GDC-0199 and CTL019.
How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?
There are a number of new targets, therapies and approaches in AML being investigated but which ones look most promising in this challenging landscape?
After a few setbacks in clinical development, some solid data is emerging with AbbVie/Genentech's ABT-199/GDC-0199 in CLL. Some more mature data at ASCO was very encouraging...
Diffuse large B cell lymphomas (DLBCL) are an aggressive subset of non-Hodgkins lymphomas that generally have a poor prognosis and a high unmet medical need. There is a raft of promising new therapies being evaluated for treatment.
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
Initial phase 2 data for Amgen's blinatumomab in B cell ALL looked encouraging 2 years ago but has it held up over time?
Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.
A review of poster data at ASCO 2014 for new drugs from new cancer drugs from $CLDX, $OMED & NuCana BioMed.
Selection of some of the many posters that caught our attention. Companies whose products are mentioned include: $EXEL, $RHHBY, $XLRN, $MRK
After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?
AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.
What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?
With the intense focus on immino-oncology, are targeted agents passe now?
A predictive biomarker for resistance to treatment by enzalutamide and abiraterone may lead to new prostate cancer drug development opportunities.
Clovis Oncology CO-1686 is in competition with AstraZeneca's AZD9291, but was it really a "loser" at ASCO 2014 as many think it was?
Final day at ASCO 2014 - what are the diehards listening to this morning?
Live blog with commentary on Day 4 of the ASCO 2014 annual meeting in Chicago.
Live blog with updates from Day 3 at ASCO 2014
Live Blog from Day 2 of ASCO 2014 in Chicago.
Coverage of day 1 at ASCO 2014 with commentary on some of the poster highlights.
Update on the top drugs in CLL including ibrutinib, obinutuzumab, idelalisib, ABT-199, GS-9973, ONO-4059, CTL019, TAK659, IPI-145, cerdulatinib and others.
Highlights in multiple myeloma at ASCO include drugs with a different mechanism of action eg panobinostat, daratumumab and elotuzumab, #ASCO14
Medivation and Astellas provided an update at AUA 2014 on the Xtandi PREVAIL data with a breakdown for visceral and non-visceral disease.
New targets are emerging in advanced prostate cancer that may help improve outcomes and overcome adaptive resistance
How we could overcome resistance to BRAF inhibitors in colon cancer with a triple combination approach
Can we improve responses to Zelboraf in advanced melanoma? The answer is a startling yes.
Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs
Update on emerging potential immuno-oncology biomarkers and combinations from AACR
Overcoming acquired resistance to therapy is a major focus in lung and prostate cancers. Check out the new developments from AACR.
Exciting new data was seen at AACR this year, including a novel ADC with a new target in melanoma, a metabolic target and understanding adaptive resistance to PI3K in breast cancer.
After disappointing results from FGFR inhibitors brivanib and dovitinib, can the next generation compounds overcome scepticism and offer better efficacy?
Immunotherapy is coming of age despite the chequered history in the past with vaccines. In part 1 we explore the state of play in lung cancer.
Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.
Pfizer's palbociclib showed promising survival data at the AACR annual meeting this weekend, but is it enough to garner approval on the basis of the phase II data?
This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.
A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.
What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.
Review of some interesting cancer pipeline drugs at AACR 2014 including TKIs and ADC therapies.
Following on from yesterday’s post on the potential for small basket trials in ER+ breast cancer with…
Today brings the launch of our series on the AACR annual meeting Previews. A variety of different…
What new clinical approaches are being investigated to overcome resistance in melanoma?
Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.
Puma Biotech are expected to present the neoadjuvant data from ISPY2 for their pan HER inhibitor, neratinib, so what's the deal?
Dr Debu Tripathy presented one of the highlights of the MBCC conference - how we can use genomics to improve clinical trials in TNBC and MBC.
Can therapy for advanced breast cancer be individualized using proteomics and genomics data?
Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas
Nearly 4 years on from the original phase 2 data at ESMO, and we learn that MetMab (onartuzumab) did not meet it's endpoint in the interim analysis of lung cancer patients with MET expression.
There has been much debate about the cardiovascular risks associated with proteasome inhibitors in multiple myeloma, but what does the data show? A synopsis of the ASH 2013 data and what we can learn in the future...
The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?
ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.
Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?
Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.
At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?
Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial
At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.
Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?
“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.
Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.
Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma.
Will they be successful despite the huge complexity involved in the underlying processes?
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies.
At ASH, the impressive data from adult and pediatric ALL was presented.
This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.
Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego
The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?
Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.
Preview of some of the key data being presented at ASCO GI in San Francisco this month.
ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).
There are some 5,000 abstarcts at ASH, many of them posters - what were the interesting nuggets this year?
BTK inhibition in the B cell receptor (BCR) pathway has been an exciting area of development over the last couple of years. What do the new competitors entering this space look like?
There was a wealth of new data in CLL at ASH but which companies or drugs were the winners and losers in New Orleans? Find out...
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.
Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.
A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium
One of the most interesting oral sessions at ASH 2013 took place on the last day and featured data on novel treatments for CLL. Data was presented on ABT-199, dinaciclib and the CAR-modified T-cell therapies in development by Novartis & Juno Therapeutics.
At ASH 2013 data on novel agents for the treatment of lymphoma was presented. This post discusses data for idelalisib in iNHL, SAR245409 in R/R Follicular Lymphoma and BAY-BAY 80-6946 (copanlisib).
ABT-199 has activity in CLL, but what about other tumor types? Check out this post to find out about a new target with potential.
With many new therapies emerging for the treatment of CLL, what criteria can physicians use to decide which therapy to give a patient?
Novartis announced this morning that their novel pan-HDAC inhibitor, panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone significantly prolonged progression-free survival (PFS) of patients with Multiple Myeloma in the phase III PANORAMA-1 trial.
Will the B cell signaling drugs work in NHL as well as CLL? What of Adcetris in front-line HL?
Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...
A review of the upcoming CLL data from the American Society of Hematology ASH meeting.
Comprehensive preview of the new developments in multiple myeloma from ASH 2013.
FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.
John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?
A lot of companies are presenting myelofibrosis data at this year's ASH annual meeting in New Orleans. This preview discusses abstracts for ruxolitinib, INCB039110, momelotinib, fedratinib, BMS-91143, pacritinib, LY2784544, pomalidomide, sonidegib.
The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...
The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.
An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).
Data presented at the World Lung Cancer conference in Sydney suggests AstraZeneca AZD9291 is now ahead of Clovis Oncology CO-1686 in the race to bring a third-generation epidermal growth factor receptor (EGFR) inhibitor to market that targets the T790M resistance mutation.
An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!
Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.
At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.
Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston
Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours
Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.
The latest data on BioMarin's PARP inhibitor BMN 673 in breast and ovarian cancer from ECCO 2013
Promising preliminary phase 1 data for AstraZeneca’s AZD9291 in T790M+ NSCLC presented today at the European Cancer Congress (ECCO 2013) is good news for lung cancer patients.
At ECCO 2013 in Amsterdam, positive data was presented from the phase 1/2 clinical trial for ODM-201 (Orion) a second generation AR antagonist. In contrast the data for ASP9521 (Astellas), a novel androgen biosynthesis inhibitor was negative.
Update on ipilimumab, AP26113, T-DM1, everolimus and others from Day 1 at the 2013 ECCO meeting in Amsterdam.
Review of the key abstracts in EML4-ALK lung cancer abstracts being presented at ECCO 2013 in Amsterdam.
A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.
Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.
Earlier this month, Janssen/Pharmacyclics announced they had submitted a New Drug Application (NDA) for FDA approval of ibrutinib, an oral Bruton’s tyrosine kinase inhibitor (BTK) in chronic lymphocytic leukemia (CLL) for the treatment of patients with a deletion of the short arm of chromosome 17 (del17p). Approval later this year or in early 2014 is highly likely given that ibrutinib has already been designated a Breakthrough Therapy by the FDA.
Takeda’s orteronel (formerly known as TAK-700) may be on its way to “dog drug heaven” after an interim analysis of the ECM-PC 5 phase 3 clinical trial showed that men with advanced prostate cancer taking the drug did not live significantly longer (HR 0.894, p=0.226) than those taking an inactive placebo.
Johnson & Johnson (JNJ) just announced the acquisition of privately-held Aragon Pharmaceuticals and the rights to ARN-509 a second-generation androgen receptor antagonist that will be a future competitor to Medivation’s Xtandi.
It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.
At ASCO 2013 the phase III MPACT trial data for Abraxane in pancreatic cancer was presented. This data was first reported at ASCO GI earlier this year. Abraxane in pancreatic cancer is a welcome new treatment option but it is not a major breakthrough that offers a dramatic shift in outcome.
At ASCO 2013, there was a lot of interest in a poster on Pfizer's PF-05280014, a potential biosimilar to Herceptin.
New clinical data on ibrutinib, obinutuzumab, idelalisib, IPI-145, ABT-199 for the treatment of Chronic Lymphocytic Leukemia (CLL) will be presented at ASCO 2013.
ASCO 2013 Preview Video of what's hot at the meeting for cancer new products in immunotherapy, CLL, breast cancer, lung cancer and breast cancer. Includes a MOA of PD-L1.
The poster sessions at the 2013 annual meeting of the American Association for Cancer Research (AACR) are not all about mice, and test tubes, but offer insights into biotech drug development, new targets and licensing opportunities.
My overriding impression of large cap Pharma R&D from the 2013 annual meeting of the American Association for Cancer Research (AACR) was that Novartis and Genentech remain the front-runners in cancer drug development, with Pfizer very much up and coming.
GDC-0032 is a next generation PI3K inhibitor that spares the beta-isoform of PI3K. Genentech hypothesize this may reduce some of the undesired side effects such as effects on metabolism, previously seen with pan PI3K inhibitors such as GDC-0941. At AACR 2013 promising early clinical data was presented for GDC-0032 in PI3KCA mutant cancers, especially breast cancer.
AACR 2013: A late-breaking clinical trial presentation to watch is LB-290: Targeting MUC16 with the Antibody-Drug Conjugate DMUC5754A in patients with platinum-resistant ovarian cancer. This data will be presented by Joyce Liu, MD, MPH from Dana-Farber Cancer Institute in the Clinical Trials Symposium on Tuesday, Apr 9 at 4.00 pm.
Tokai Pharmaceuticals have yet to show the new formulation of galeterone is safe and effective or that men with advanced prostate cancer live longer when taking the drug compared to taking abiraterone or enzalutamide either sequentially, or in combination. While galeterone may offer an innovative mechanism of action, it is too early to say what potential it may have in the treatment of advanced prostate cancer.
ASCO GU 2013: dasatinib phase 3 clinical trial fails to show any survival benefit in men with advanced prostate cancer when used in combination with docetaxel chemotherapy. However whether there are a subset of advanced prostate cancer patients who might respond to the bone-targeted effects of the drug remains open to question.
At the ASCO GU 2013 meeting in Orlando, Bristol Myers Squibb will publish the results of the dasatinib (Sprycel) phase 3 prostate cancer trial. New data on abiraterone, alpharadin, ARN-509 and enzalutamide is also expected.
For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
ABT-199 is an exciting new agent in development with potential as a new treatment option for CLL & MCL. It is a potent and selective BCL-2 inhibitor that has been engineered not to cause the dose-dependent thrombocytopenia seen with navitoclax.
Medivation investors hoping for a windfall will be disappointed to hear that on December 20, 2012 a California judge ruled the company had no rights to what is now known as Aragon Pharmaceuticals ARN-509, a next-generation androgen receptor (AR) antagonist for advanced prostate cancer, similar in chemical structure to enzalutamide (Xtandi)
Dr Hagop Kantarjian from The MD Anderson Cancer in Houston discussed chronic myeloid leukemia (CML) treatment options at the 2012 Chemotherapy Foundation Symposium in New York.
AB Science has filed for European approval of mastinib in pancreatic cancer with the European Medicines Agency based on data that showed masitinib significantly increased survival in a subset of patients with a novel genetic biomarker. Data will be presented at 2013 ASCO GI symposium.
ODM-201 is a second generation androgen-receptor AR antagonist from Orion Pharma in early stages of clinical development.
Results were presented at ESMO 2012 for the TH-CR-404 phase 2 clinical trial that compared the efficacy and safety of TH-302 (Threshold Pharmaceuticals) plus gemicitabine versus gemcitabine alone in patients with untreated advanced pancreatic cancer.
One of the late-breaking abstracts that I am looking forward at the forthcoming annual Congress of the European Society for Medical Oncology (ESMO 2012) in Vienna is on ODM-201, a new prostate cancer drug from Orion Pharma.
FDA approves first artificial retina prosthesis, the Argus II from Second Sight. This is not a bionic eye. To date, only crude images can be detected. There is no dramatic restoration of sight or vision, instead retinal prostheses currently only offer the ability to detect light and large shapes. Several companies and research groups including Bionic Vision Australia are working on innovative retinal prostheses that aim to restore some vision.
Preview of late breaking abstracts to be presented in Presidential Symposia at the European Society of Medical Oncology ESMO 2012 Congress in Vienna
Swedish researchers describe how a panel of five cerebrospinal fluid (CSF) biomarkers allowed the differential diagnosis of common dementia from Parkinsonian disorders.
Biomarkers can be used for diagnosis and for monitoring the safety and effectiveness of treatments. They are increasingly becoming important in the selection of patients for clinical trials, and as potential surrogates for clinical endpoints that may take a long time to occur e.g. measuring how long someone will live in a cancer trial (overall survival).
Detecting thyroid cancer early and avoiding unnecessary surgery is the potential promise of a new diagnostic test.
A diagnosis of stage IV pancreatic cancer is pretty much a death sentence. There is, therefore, an unmet need for effective new pancreatic cancer treatments.
Piramal Healthcare presented posters on early-stage drug development compounds, including: P7170, a Phosphoinositide 3-Kinase (PI3K)-mammalian Target of Rapamycin (mTOR) and Activin Receptor-Like Kinase 1 (ALK1) inhibitor & P2745, an orally bioavailable molecule effective in imatinib resistant chronic myeloid leukemia cell lines including those with the T315i mutation.
ABT-199, a potent and selective inhibitor of Bcl-2. Steven Elmore from Abbott Laboratories presented impressive early data from an ongoing phase I trial in patients with chronic lymphocytic leukemia (CLL).
Dr Hussain discusses the scientific rationale behind the mechanism of action for cabozantinib, a multi-kinase inhibitor of C-MET, VEGF and others.
At the 2011 ASCO annual meeting, Dr Hussain presented data from a non-randomized phase 2 trial with cabozantinib that showed dramatic improvements in bone scans before and after treatment.
"My average patient is interested in living longer, not just in controlling their pain." Dr Maha Hussain
Orteronel (TAK-700) is a selective, non-steroidal inhibitor of 17, 20 lyase, a key enzyme involved in the production of androgens such as testosterone. This is a similar mode of action to abiraterone acetate (Zytiga).
radium-223 in bone-metastatic castration resistant prostate cancer patients (CRPC), not only significantly prolonged time to first skeletal related event (SRE), but significantly prolonged 3 out of the 4 SRE components.
Low-level expression of micro RNA-375 (miR-375) correlated with poor outcome in tumors of HNSCC patients.
My preview of prostate cancer abstracts that caught my attention.
The South Korean equivalent of the FDA have approved radotinib (Il-Yang pharmaceuticals) or chronic myeloid leukemia (CML).